Healthcare Innovations for Canadians

Valeo Pharma is committed to provide healthcare professionals and patients with innovative therapeutic solutions to improve quality of life.

April is #ParkinsonAwarenessMonth!

April 11 is World Parkinson's Day, and time for the Parkinson Disease (PD) community to come together to raise awareness and help advance research towards improved therapies and a cure. PD is a long-term neurodegenerative disease that is caused by the loss of specific nerve cells in the brain. As a result, many Parkinson patients suffer from motor symptoms such as tremor, rigidity, as well as speech and walking impairment. Patients can also experience non-motor related symptoms which can have a significant impact on the quality and the maintenance of an active lifestyle. Over 100,000 Canadians and their families suffer from PD.

Help us as we join with Parkinson Canada to raise awareness about PD.

Valeo Pharma is also committed to helping improve patient care for PD patients in Canada and to providing new treatment options. We are looking forward to the launch of Onstryv® (safinamide), the first new oral treatment for Parkinson's disease in over a decade.

Onstryv® (safinamide)


Synacthen® Depot
Ethacrynate Sodium


Valeo Pharma Inc. has built its business on a foundation of strong partnerships with Global pharmaceutical companies. We look for partners with world class R&D and state of the art manufacturing facilities to expand our own internal capabilities.


Valeo Pharma is a fully integrated Canadian Specialty Pharmaceutical company building successful strategic partnerships to deliver therapeutic solutions to Healthcare Professionals, and patients with unmet medical needs.

About Valeo Pharma

Driven by our experienced management team with in-depth knowledge of the Canadian market conditions and long-standing relationships with key industry leaders and healthcare professionals, our solid business model provides the required resources to successfully introduce specialty pharmaceutical products to Canada.